ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals Inc. is advancing its RNAi therapeutic zilebesiran into a global Phase 3 cardiovascular outcomes trial, building on promising results from the KARDIA Phase 2 program and positioning the company for a potential breakthrough in…

Alnylam Pharmaceuticals has delivered a strong financial performance, exceeding expectations and setting a new benchmark for its peers in the healthcare sector, solidifying its position as a leader in the biotechnology industry.

Alnylam Pharmaceuticals Inc. has made significant strides in recent developments, including EU approval of its transthyretin amyloidosis treatment and strong earnings expectations, positioning the company for continued growth and innovation.

Alnylam Pharmaceuticals Inc. has seen a robust stock performance, reaching a 52-week high, with analysts and experts expressing optimism about the company’s future growth prospects.

Alnylam Pharmaceuticals has appointed a new Chief R&D Officer and reached an all-time stock high, reflecting investor confidence in the company’s growth trajectory and innovative RNAi therapeutics.

Alnylam Pharmaceuticals Inc. has seen its stock price surge to a new high of $304.52, driven by optimistic analyst forecasts and the company’s commitment to innovation in the biotechnology sector.

Alnylam Pharmaceuticals Inc. exceeded Wall Street expectations in Q1 2025, driven by strong revenue and regulatory milestones, positioning the company as a key player in the development of innovative RNAi therapeutics.

Alnylam Pharmaceuticals has received a positive opinion from the European Medicines Agency’s CHMP for its RNA interference therapeutic, vutrisiran, for the treatment of ATTR amyloidosis with cardiomyopathy.